다낭성난소증후군 환자에서 Pioglitazone이 인슐린 민감도, 난소 기능, 난소 기질 내 혈류에 미치는 영향 = Effects of Pioglitazone on Insulin Sensitivity, Ovarian Function and Intraovarian Stromal Blood Flow in Women with Polycystic Ovary Syndrome

다국어 초록 (Multilingual Abstract)

Objective: This study was performed to investigate the effects of pioglitazone, an insulin sensitizing agent, on insulin resistance, ovarian function and intraovarian stromal blood flow in patients with polycystic ovarian syndrome (PCOS). Material and Methods: Thirty patients with PCOS, aged 18~34 years, were recruited. Criteria for diagnosis of PCOS were as defined in 2003 Rotterdam consensus. They were treated for 6 months with pioglitazone at a dose of 30 mg/day orally. The hormonal blood profile, fasting serum glucose levels, a glycemic response to 75 g oral glucose tolerance test (OGTT), and an ovarian stromal artery (OSA) blood flow were assessed at baseline and after 6 months of treatment. Results: Eighteen (60.0%) of 30 patients treated with pioglitazone demonstrated a spontaneous ovulation After pioglitazone treatment, fasting insulin concentrations, serum glucose levels after 75 g OGTT significantly decreased (p=0.001, p=0.04, respectively), and fasting glucose to insulin (G/I) ratio significantly increased (p<0.001). The pioglitazone treatment induced a significant reduction in serum LH, testosterone (T) and free T levels (p<0.001, p=0.02, p=0.002, respectively). The resistance index (RI) values of OSA significantly increased after treatment (p<0.001). In analyzing pioglitazone-treated patients according to their body mass index (BMI), nonobese group as well as obese group showed a significant improvement in fasting G/I ratio (p<0.01). The pioglitazone treatment induced a significant reduction in serum LH and free T levels in nonobese group (p<0.001, p<0.05, respectively) as well as obese group (p=0.001, p<0.05, respectively). The RI values of OSA significantly increased in both nonobese and obese groups after pioglitazone treatment (p<0.001, p=0.003, respectively). Conclusions: Pioglitazone could ameliorate the glycoinsulinemic metabolism, and this beneficial effects of this drug could improve the endocrine-reproductive condition associated with the decrease of ovarian stromal artery blood flow, in both nonobese and obese patients with PCOS.

참고문헌 (Reference)

1 "Utero-ovarian arterial blood flow and hormonal profile in patients with polycystic ovary syndrome" 13 : 815-21, 1998

2 "Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome" 82 : 661-5, 2004

3 "The role of ultrasound and Doppler analysis in the diagnosis of polycystic ovary synd- rome" 22 : 225-32, 2003

4 "The role of color Doppler ima- ging in the diagnosis of polycystic ovary syndrome" 172 : 108-13, 1995

5 "The assessment of in- sulin resistance in man" 19 : 527-34, 2002

6 "Revised 2003 consen- sus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome" 19 : 41-7, 2004

7 "Responses of Serum Androgen and Insulin Resistance to Met- formin and Pioglitazone in Obese, Insulin-resistant Women with Polycystic Ovary Syndrome." 2005

8 "Polycystic ovary syndrome:relation- ship between insulin sensitivity,sex hormone levels and ovarian stromal blood flow" 15 : 142-9, 2001

9 "Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate." 44 : 23-7, 1999

10 "Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin" 18 : 1618-25, 2003

11 "Pharmacokinetics and clinical efficacy of pioglitazone" 121 : 19-25, 2001

12 "Pathogenesis of polycystic ovary synd- rome:what is the role of obesity" 53 : 358-76, 2004

13 "Ovarian pathology associated with insulin resistance and acanthosis nigricans" 58 : 662-4, 1981

14 "Metformin effects on clinical features, endocrine and metabolic profiles, and in- sulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6？month trial, followed by open, long-term clinical evaluation" 86 : 139-46, 2000

15 "Luteinizing Hormone Secretion is Not Influenced by Insulin Infusion in Women with Polycystic Ovary Syndrome Despite Improved Insulin Sensitivity During Pioglitazone Treatment" 2005

16 "Insulin-lowering drugs in polycystic ovary syndrome" 28 : 153-64, 2001

17 "Insulin-lowering agents in the management of polycystic ovary synd- rome" 24 : 633-67, 2003

18 "Insulin rece- ptors in the central nervous system:localization,signalling mechanisms and functional aspects" 36 : 343-62, 1991

19 "Insulin and polycystic ovary syndrome:a new look at an old subject" 12 : 277-92, 1998

20 "Effect of thiazolidi- nediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats" 284 : 1125-30, 2003

21 "Effect of the insulin sensitizer pioglitazone on in- sulin resistance,hyperandrogenism,and ovulatory dysfunction in women with polycystic ovary synd- rome" 89 : 3835-40, 2004

22 "Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS) comparison between nonobese and obese adolescents" 88 : 4682-8, 2003

23 "Body composition charac- teristics and body fat distribution in lean women with polycystic ovary syndrome" 16 : 1255-60, 2001

24 "Antiinflammatory and antiarterioscle- rotic effects of pioglitazone" 40 : 687-93, 2002